Can Biotech Kill the Flu Once and For All?

+ more

Biotech is essential for advancing science. Biotechnology is a broad term that involves the use of living organisms to develop new products. Over the years innovations in the space have created lifesaving medications and tools, but its work can also be behind simple items found in our homes. Alcohol production is the perhaps the most basic example, with beer being made of yeast and sugar-converting enzymes. Some household products come directly from cells, like washing detergents and cosmetics.

Industrial biotechnology is most significantly used to create new medicines that have been previously difficult to produce. Bio research is making leaps and bounds into futuristic ways of thinking. In 2018, the United Nations gave cautious approval for gene drive therapy.

This is where scientists can genetically mutate mosquito genes to create infertility among the insect in Burkina Faso, Africa. The project is called Target Malaria, a non-profit funded by the Bill and Melinda Gates Foundation. Engineer gene drives in mosquitoes will hopefully kill out infection-carrying insects.

Human epidemics like the flu might be finally eradicated with the use of biotechnology. The flu virus is very difficult to control as it mutates at a rapid rate. Scientists are currently using data to forecast the strains to create vaccines resistant to the flu. Currently, there is a lot of funding, $160 million, going into a universal flu vaccine. It is possible that breakthroughs will be seen this year.

For many, biotechnology may be the only hope for their survival. With many diseases such as Leukemia and Sickle Cell disease, patients rely on bone marrow transplants to revive their immune systems. Although these transplants can be the only cure for some, they can be risky. Doctors at City of Hope Hospital in Pasadena, California are leaning towards CAR-T cell therapies as a safer treatment for patients at critical stages of their disease.

CAR-T cell therapy is a form of gene editing. If a patient has a genetic deficiency that is leading to their illness, genes can now be injected to fight the disease.

Last September, Sangamo Therapeutics in Richmond, California shared that it had injected gene-editing enzymes into a patient. The therapy corrected a genetic deficiency that prevented him from breaking down complex sugars. The therapy worked and now clinical trials are being done to see if this is a safe therapy for all.

Neuroscience has also taken an interest in biotech in a sci-fi kind of way. Elon Musk is seeking to develop brain interfaces that could work with an individual’s neurology. The thought is that these implanted bio particles could help those who suffer from tremors, paralysis, nerve damage and memory loss. These devices could work autonomously with the brain’s neurological waves and help by applying electrical stimulation to reduce a patient’s ailments.

2019 may be the year that scientists decide to cut the cord and fine-tune new neurological treatments.

Biotechnology looks at science from the root source and finds solutions to problems by using the bones of life. Cells and enzymes have the ability to morph and fill gaps that have been created by outside destruction. Expect to see biotech flourish in 2019.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter –
Facebook –
LinkedIn –


Will Chipotle’s Investment In Education Pay Off For Its Employees?
April 20, 2021
Chipotle launched its new debt-free tuition program for its employees. The program will cover those majoring in agriculture, culinary, and hospitality industries. The move shows intention for how the Read more
Track to the Future: Array Technologies Achieves ISO 9001:2015 Certification
April 20, 2021
Array Technologies recently completed its ISO audits and ISO certification. This exciting step in Array Technologies' growth was the main topic of conversation for this episode of Track to the Future. Travis Read more
E2B: Energy Industry Cybersecurity Threats In The Digital Age
April 20, 2021
  Are energy companies taking cybersecurity seriously? Are they shifting focus to application security? E2B host Daniel Litwin speaks with Dan Cornell, Chief Technology Officer of the Denim Group and Kent Read more